Amedisys Inc Stock News

DekaBank Deutsche Girozentrale decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 80.0% in the 3rd quarter, Holdings Channel reports. The fund owned 3,782 shares of the health services providers stock after selling 15,091 shares during the quarter. DekaBank Deutsche Girozentrales holdings in Amedisys were worth $561,000 as of its most recent filing with []

TheStreet cut shares of Amedisys (NASDAQ:AMED) from a b- rating to a c rating in a report released on Friday, TheStreetRatingsTable reports. Several other analysts have also recently weighed in on AMED. Royal Bank of Canada cut their price target on shares of Amedisys from $244.00 to $221.00 and set an outperform rating on the […]

Kestra Private Wealth Services LLC bought a new position in Amedisys, Inc. (NASDAQ:AMED) during the 3rd quarter, Holdings Channel reports. The fund bought 6,505 shares of the health services providers stock, valued at approximately $970,000. Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Eubel Brady & []

Bell Bank lifted its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 5.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,991 shares of the health services providers stock after purchasing an additional 329 shares during the quarter. Bell Banks holdings in Amedisys were []

WALTHAM, Mass.--(BUSINESS WIRE)--connectRN Inc., a tech-enabled platform built to improve clinicians lives through access to community, opportunity, and support, today announced it has completed a $76M financing, bringing its total raised to over $100M to date. Suvretta Capital Management and Avidity Partners co-led the round, along with HBM Healthcare Investments, Infinitum Asset Management, Adage Capital Management, Cormorant Asset Management and Park West Asset Management. Amedisys, a leade

Equities research analysts expect that Amedisys, Inc. (NASDAQ:AMED) will post $555.84 million in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Amedisys earnings, with the highest sales estimate coming in at $567.10 million and the lowest estimate coming in at $550.60 million. Amedisys posted sales of $550.71 million during []

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.

AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.

BATON ROUGE, La., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul

BATON ROUGE, La., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Bank of America Securities 2021 Virtual Healthcare Conference on December 6 at 9:00 a.m. Eastern.

BATON ROUGE, La., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B.

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.

COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.